Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefixime for Early Syphilis
NCT03660488Phase 2Completed
- Sponsor
- University of California, Los Angeles
- Start
- Sep 2018
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cefixime in syphilis (2 arms), sponsored by University of California, Los Angeles. Primary endpoint: Serological Treatment Response at 6 months. Started Sep 2018; status: completed.
02
Drugs
cefixime
03
Conditions
syphilis
Beyond the preview
Go deeper on NCT03660488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03660488.